Literature DB >> 19338769

bFGF rescues imatinib/STI571-induced apoptosis of sis-NIH3T3 fibroblasts.

Mitsuhiro Ohshima1, Yoko Yamaguchi, Kai Kappert, Patrick Micke, Kichibee Otsuka.   

Abstract

PDGF-B-transfected, sis-NIH3T3 fibroblasts serve as a model system for examining the role of PDGF signaling in tumors. We have found that imatinib/STI571, a tyrosine kinase inhibitor targeting PDGF receptors, induces apoptosis of sis-NIH3T3 fibroblasts cultured under serum free conditions, which was rescued by the addition of 10% newborn calf serum (NCS). Therefore, growth factors included in serum were tested with regard to their ability to rescue imatinib-induced apoptosis. While PDGF-AB, EGF, and IGF-I failed to protect imatinib-induced sis-NIH3T3 cell apoptosis, bFGF rescued it. The effects of bFGF were confirmed by both cell viability assays and Bax/Bcl-2 gene expression ratio. An FGF receptor inhibitor, PD166866, invalidated the protective effect of bFGF. However, combination of imatinib and PD166866 failed to induce cell death of sis-NIH3T3 cells when cultured in 10% NCS. These results indicate that synergistic administration of some types of tyrosine kinase inhibitors need to be tested under in vivo-like conditions to establish novel strategies in anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19338769     DOI: 10.1016/j.bbrc.2009.02.012

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Heparin-functionalized collagen matrices with controlled release of basic fibroblast growth factor.

Authors:  J M Wu; Y Y Xu; Z H Li; X Y Yuan; P F Wang; X Z Zhang; Y Q Liu; J Guan; Y Guo; R X Li; H Zhang
Journal:  J Mater Sci Mater Med       Date:  2010-11-04       Impact factor: 3.896

2.  Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.

Authors:  Cecilia Sgadari; Giovanni Barillari; Clelia Palladino; Stefania Bellino; Brunella Taddeo; Elena Toschi; Barbara Ensoli
Journal:  Int J Vasc Med       Date:  2011-10-09

3.  Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients.

Authors:  Thomas K Kilvaer; Andrej Valkov; Sveinung W Sorbye; Eivind Smeland; Roy M Bremnes; Lill-Tove Busund; Tom Donnem
Journal:  J Transl Med       Date:  2011-07-06       Impact factor: 5.531

4.  The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.

Authors:  Thomas K Kilvaer; Eivind Smeland; Andrej Valkov; Sveinung W Sorbye; Roy M Bremnes; Lill-Tove Busund; Tom Donnem
Journal:  BMC Clin Pathol       Date:  2014-01-20

5.  The synthetic inhibitor of fibroblast growth factor receptor PD166866 controls negatively the growth of tumor cells in culture.

Authors:  Gianfranco Risuleo; Marina Ciacciarelli; Mauro Castelli; Gaspare Galati
Journal:  J Exp Clin Cancer Res       Date:  2009-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.